Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study
Clinical studies treating pediatric and adult solid tumors, such as glioblastoma (GBM), with a triple-drug regimen of temozolomide (TMZ), bevacizumab (BEV), and irinotecan (IRI) [TBI] have demonstrated various efficacies, but with no unexpected toxicities. The TBI regimen has never been studied in r...
Main Authors: | Guangrong Lu, Mayank Rao, Ping Zhu, Buqing Liang, Rasheda T. El-Nazer, Ekokobe Fonkem, Meenakshi B. Bhattacharjee, Jay-Jiguang Zhu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-01-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fneur.2019.00042/full |
Similar Items
-
Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series
by: George Ansstas, et al.
Published: (2016-01-01) -
Bevacizumab, irinotecan, and temozolomide with re-irradiation in adult recurrent medulloblastoma: A first case report
by: Takahiro Yamauchi, et al.
Published: (2021-09-01) -
Molecular Evolution of a Glioblastoma Controlled With Tumor Treating Fields and Concomitant Temozolomide
by: H. Ian Robins, et al.
Published: (2018-10-01) -
Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma
by: Mario E. Lacouture, et al.
Published: (2020-07-01) -
Long term survival in a patient with recurrent metastatic Ewing sarcoma treated with irinotecan and temozolomide
by: Hakan Gelincik, et al.
Published: (2016-12-01)